JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: Contribution, diagnosis and therapeutic prospects

Pathologie Biologie

Volumn 59, Issue 4, 2011, Pages

  Benmoussa, A ^a   Dehbi, H ^a   Fehri, S ^b   Quessar, A ^b   Nadifi, S ^a  

^a Faculty of Medicine   (Morocco)

^b IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

Author keywords

AS PCR; Essential thrombocythemia; Idiopathic myelofibrosis; JAK2 V617F; Myeloproliferative disorders in Morocco; Polycythemia vera

Indexed keywords

GENOMIC DNA; HEMOGLOBIN;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE FUNCTION; GENETIC SCREENING; HEMATOCRIT; HETEROZYGOTE; HUMAN; JAK2 GENE; LEUKOCYTOSIS; MALE; MOROCCO; MUTATIONAL ANALYSIS; MUTATOR GENE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; THROMBOCYTOSIS;

ADOLESCENT; ADULT; AGED; FEMALE; GENE FREQUENCY; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOROCCO; MUTATION; MYELOPROLIFERATIVE DISORDERS;

EID: 80051573784     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2009.06.005     Document Type: Article

References (19)

1. Eibl B., Ebner S., Duba C., Bock G., Romani N., Erdel M., et al. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 1997, 20:215-223.
2. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
3. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
4. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
5. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
6. Saharinen P., Vihinen M., Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003, 14:1448-1459.
7. Lindauer K., Loerting T., Liedl K.R., Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng 2001, 14:27-37.
8. Zhou Y.J., Chen M., Cusack N.A., Kimmel L.H., Magnuson K.S., Boyd J.G., et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell 2001, 8:959-969.
9. Passamonti F., Randi M.L., Rumi E., Pungolino E., Elena C., Pietra D., et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (V617F) mutation. Blood 2007, 110:485-489.
10. McClure R., Mai M., Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006, 20:168-171.
11. Gusset W. Test sudent the probale error of a mean. Biometrika 1908, 6:1-25.
12. Speletas M., Katodritou E., Daiou C., Mandala E., Papadakis E., Kioumi A., et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 2006, 1053-1062.
13. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., et al. occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162-2168.
14. Steensma D.P., DewaldGW, Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplasticsyndromes. Blood 2005, 106:1207-1209.
15. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., et al. Identification of an acquired JAK2 mutation in polycythemia vera. Biol Chem 2005, 280:22788-22792.
16. Scott M., Ross W.T., Levine L., Mike A., Michael R. Stratton A: Jak2 exon12 mutation in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 357(14):1457.
17. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders:a study of 1182 patients. Blood 2006, 10:3472-3476.
18. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366:1945-1953.
19. Kiladjian J.J., Casadevall N., Vainchenker W., Fenaux P. The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. Pathologie Biologie 2007, 55:85-87.